Olutasidenib plus targeted therapy for relapsed IDH1-mutated myeloid cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or MDS/MPN overlap (with at least 10% blasts in blood or bone marrow).
- You have a confirmed IDH1 mutation in your cancer cells.
- You also have an additional mutation in one or more of these genes: KRAS, NRAS, PTPN11, CBL, NF1, FLT3-ITD, FLT3-TKD, KIT, JAK2, MPL, CALR, or CSF3R.
- You are able to take oral medications and have adequate kidney and liver function as determined by blood tests.
- You have not been previously treated with olutasidenib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
This trial combines three drugs—decitabine, venetoclax, and a targeted therapy (olutasidenib)—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It may also be an option for people newly diagnosed with AML who cannot receive intense chemotherapy.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.